• Explore /
  • Poster
  • / Abexinostat (ABX) as a means to reverse pazopanib (PAZ) resistance: A phase 1 study in advanced solid tumor malignancies.

Abexinostat (ABX) as a means to reverse pazopanib (PAZ) resistance: A phase 1 study in advanced solid tumor malignancies.

Abstract Poster

Authors

null

Rahul Raj Aggarwal

University of California, San Francisco, San Francisco, CA

Rahul Raj Aggarwal , Scott Thomas , Jennifer A. Grabowsky , Armand Harb , Jim Leng , Anne Reinert , Ilaria Mastroserio , Thach-Giao Truong , Pamela N. Munster

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

Track

Developmental Therapeutics and Translational Research

Sub Track

Small Molecules

Clinical Trial Registration Number

NCT01543763

Citation

J Clin Oncol 34, 2016 (suppl; abstr 2519)

DOI

10.1200/JCO.2016.34.15_suppl.2519

Abstract #

2519

Poster Bd #

219

Abstract Disclosures

Similar Posters

First Author: Rahul Raj Aggarwal

First Author: Rahul Raj Aggarwal

First Author: Thach-Giao Truong

First Author: Christian K. Kollmannsberger